Cargando…
HER-2/neu Testing and Therapy in Gastroesophageal Adenocarcinoma
Despite ongoing advances in the treatment of gastroesophageal cancer, prognosis remains poor. The best promise to improve this poor survival is provided by new targeted agents. Of these, human epidermal growth factor receptor 2 (HER2) is currently in the spotlight. In this review, we provide an over...
| Autores principales: | , , , |
|---|---|
| Formato: | Texto |
| Lenguaje: | English |
| Publicado: |
SAGE-Hindawi Access to Research
2010
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3005843/ https://www.ncbi.nlm.nih.gov/pubmed/21188213 http://dx.doi.org/10.4061/2011/674182 |